clinical trial · NCT04293185
A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease
Sickle Cell Diseasebb1111
brief summary
This is a non-randomized, open-label, multi-site, single-dose, Phase 3 study in approximately 35 adults and pediatric subjects ≥2 and ≤50 years of age with sickle cell disease (SCD). The study will evaluate hematopoietic stem cell (HSC) transplantation (HSCT) using bb1111 (also known as LentiGlobin BB305 Drug Product for SCD).
started
Feb 14, 2020
primary completion
May 1, 2027
completion
Nov 1, 2027
last updated
Dec 10, 2024
official title
A Phase 3 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With the BB305 Lentiviral Vector in Subjects With Sickle Cell Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol